David Hsia - Tanvex BioPharma Chief Technology Officer, Director
| 6541 Stock | TWD 66.10 1.50 2.22% |
Director
David Hsia is Chief Technology Officer, Director of Tanvex BioPharma since 2020.
| Tenure | 4 years |
| Web | https://www.tanvex.com |
Tanvex BioPharma Management Efficiency
The company has return on total asset (ROA) of (0.2041) % which means that it has lost $0.2041 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.603) %, meaning that it generated substantial loss on money invested by shareholders. Tanvex BioPharma's management efficiency ratios could be used to measure how well Tanvex BioPharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | DIRECTOR Age | ||
| Taychang Wang | OBI Pharma | N/A | |
| LungYeh Cho | TaiMed Biologics | N/A | |
| Howard Lee | TaiMed Biologics | N/A | |
| MingChing Chen | TaiMed Biologics | N/A | |
| Frank Chen | OBI Pharma | N/A | |
| ChungMing Chang | OBI Pharma | N/A | |
| LungYeh Cho | OBI Pharma | N/A | |
| LuPing Chow | TaiMed Biologics | N/A | |
| Jerry Fong | OBI Pharma | N/A | |
| Tamon Tseng | TaiMed Biologics | N/A | |
Management Performance
| Return On Equity | -0.6 | |||
| Return On Asset | -0.2 |
Tanvex BioPharma Leadership Team
Elected by the shareholders, the Tanvex BioPharma's board of directors comprises two types of representatives: Tanvex BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tanvex. The board's role is to monitor Tanvex BioPharma's management team and ensure that shareholders' interests are well served. Tanvex BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tanvex BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lin Chen, Chief Executive Officer, Chief Financial Officer, Head of Finance, Director | ||
| Val Chen, Director Officer | ||
| Helena Makagiansar, Deputy General Manager-LJB Production Development | ||
| Yongjian Wu, Deputy General Manager-LJB Research & Development | ||
| LungYeh Cho, Director | ||
| Dilip Joshi, VP US | ||
| LeeChiou Chang, Independent Director | ||
| FACP FACP, Pres Chairman | ||
| Lily Yuan, Site LJB | ||
| K Lin, Co CFO | ||
| Linda Grillo, Director Marketing | ||
| Zheng Xia, Chief Officer | ||
| Mike Parker, Senior Deputy General Manager-Technology | ||
| ChiChuan Chen, Chairman of the Board | ||
| Allen Chao, Chairman of the Board, Chief Executive Officer, General Manager | ||
| Yun Yen, Director | ||
| David Hsia, Chief Technology Officer, Director | ||
| Kaiwen Yang, Deputy General Manager-LJB Production | ||
| Tamon Tseng, Director | ||
| Chuan Shih, Independent Director | ||
| JinPau Tsai, Independent Director |
Tanvex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tanvex BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (76.42) % | |||
| Current Valuation | 14.19 B | |||
| Shares Outstanding | 352.74 M | |||
| Shares Owned By Insiders | 53.74 % | |||
| Shares Owned By Institutions | 4.30 % | |||
| Price To Book | 7.12 X | |||
| Price To Sales | 681.78 X | |||
| Revenue | 5.41 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.